Skip to content Skip to footer

INSIGHTS+

Insights+: The US FDA New Drug Approvals in July 2020
Insights+: The US FDA New Drug Approvals in July 2020
The US FDA has approved multiple NDAs and BLAs in July 2020, leading to treatments for patients and advances in the health care industry. The Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) have approved 59 novel products so far in 2020, including 8 in July 2020. Additionally,…
Insights+ Key Biosimilars Events of July 2020
Insights+ Key Biosimilars Events of July 2020
Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Cadila expanded its footprints in India with the launch of its two biosimilars Bevaro (bevacizumab, biosimilar) and Ritucad (rituximab, biosimilar) Our team at PharmaShots has summarized 9 key events of the biosimilar space of July 2020 1. Samsung…
Insights+: COVID-19 Healthcare News Monthly Updates - July 2020
Insights+: COVID-19 Healthcare News Monthly Updates – July 2020
Our planet is facing a major pandemic outbreak due to COVID-19 and health agencies are taking every measure to stop it The outbreak of the respiratory disease was first detected in Wuhan City, Hubei Province, China in Dec 2019  PharmaShots is keeping a track of all of the important updates in the Life-sciences sector, where…
Insights+: The US FDA New Drug Approvals in June 2020
Insights+: The US FDA New Drug Approvals in June 2020
The US FDA has approved multiple NDAs and BLAs in Jun 2020, leading to treatments for patients and advances in the health care industry. The Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) have approved 51 novel products so far in 2020, including 8 in Jun 2020. Additionally,…
PharmaShots' Key Highlights of Second Quarter 2020
PharmaShots’ Key Highlights of Second Quarter 2020
The second quarter of 2020 has ended with big approvals in pharma and biotech industry. Moving with the latest approval of Roche's Phesgo and Enspryng & Zogenix's Fintepla. Highlights of the quarter is COVID-19 as the development of vaccines and drugs were on peak. Celltrion evaluated Remsima (biosimilar, infliximab) against COVID-19 in the UK. The…
Insights+ Key Biosimilars Events of June 2020
Insights+ Key Biosimilars Events of June 2020
Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Mylan with its partners Lupin and Biocon received MAA for Nepexto (biosimilar, etanercept) in EU and the US FDA's Approval for Semglee (biosimilar, insulin glargine) respectively Our team at PharmaShots has summarized 15 key events of the…
Insights+: COVID-19 Healthcare News Monthly Updates - June 2020
Insights+: COVID-19 Healthcare News Monthly Updates – June 2020
Our planet is facing a major pandemic outbreak due to COVID-19 and health agencies are taking every measure to stop it The outbreak of the respiratory disease was first detected in Wuhan City, Hubei Province, China in Dec 2019. PharmaShots is keeping a track of all of the important updates in the Lifesciences sector, where…
Insights+: The US FDA New Drug Approvals in May 2020
Insights+: The US FDA New Drug Approvals in May 2020
The US FDA has approved multiple NDAs and BLAs in May 2020, leading to the treatments for patients and advances in the health care industry  The Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) have approved 43 novel products so far in 2020, including 12 in May 2020…
Insights+ Key Biosimilars Events of May 2020
Insights+ Key Biosimilars Events of May 2020
Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Fresenius Kabi expanded its footprints with the acceptance of MAA and BLA of its MSB11455 (biosimilar, pegfilgrastim) in the EU and the US respectively, and also signed an agreement with Medec to commercialize Idacio (adalimumab, biosimilar) in…
Insights+: Key Events of ASCO 2020 Virtual Annual Meeting #ASCO20
Insights+: Key Events of ASCO 2020 Virtual Annual Meeting #ASCO20
The American Society of Clinical Oncology (ASCO) is a platform for cancer experts to share views on the latest advancements and new approaches in cancer research and was held virtually this year due to the COVID-19 pandemic Janssen highlights its oncology portfolio, Merck & Pfizer demonstrated the potential of Bavencio in GTT while AstraZeneca showcased…